PMC:7441788 / 40977-41313 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T171","span":{"begin":30,"end":38},"obj":"Disease"},{"id":"T172","span":{"begin":306,"end":314},"obj":"Disease"}],"attributes":[{"id":"A171","pred":"mondo_id","subj":"T171","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A172","pred":"mondo_id","subj":"T172","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"A prospective study of HCQ on COVID-19 patients (13 cases) admitted to the ICU in France showed that the first daily dose of 800 mg/1 time for 1 day, and 200 mg/2 times/day for 7 days was recommended to maintain the HCQ treatment level (1–2 mg/l) based on physiologically pharmacokinetic (PBPK) models for COVID-19 patients in ICU [67]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T299","span":{"begin":0,"end":1},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"A prospective study of HCQ on COVID-19 patients (13 cases) admitted to the ICU in France showed that the first daily dose of 800 mg/1 time for 1 day, and 200 mg/2 times/day for 7 days was recommended to maintain the HCQ treatment level (1–2 mg/l) based on physiologically pharmacokinetic (PBPK) models for COVID-19 patients in ICU [67]."}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T151","span":{"begin":30,"end":38},"obj":"Species"},{"id":"T152","span":{"begin":306,"end":314},"obj":"Species"}],"attributes":[{"id":"A151","pred":"ncbi_taxonomy_id","subj":"T151","obj":"NCBItxid:2697049"},{"id":"A152","pred":"ncbi_taxonomy_id","subj":"T152","obj":"NCBItxid:2697049"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"A prospective study of HCQ on COVID-19 patients (13 cases) admitted to the ICU in France showed that the first daily dose of 800 mg/1 time for 1 day, and 200 mg/2 times/day for 7 days was recommended to maintain the HCQ treatment level (1–2 mg/l) based on physiologically pharmacokinetic (PBPK) models for COVID-19 patients in ICU [67]."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T280","span":{"begin":0,"end":336},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"A prospective study of HCQ on COVID-19 patients (13 cases) admitted to the ICU in France showed that the first daily dose of 800 mg/1 time for 1 day, and 200 mg/2 times/day for 7 days was recommended to maintain the HCQ treatment level (1–2 mg/l) based on physiologically pharmacokinetic (PBPK) models for COVID-19 patients in ICU [67]."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"1491","span":{"begin":39,"end":47},"obj":"Species"},{"id":"1492","span":{"begin":315,"end":323},"obj":"Species"},{"id":"1506","span":{"begin":23,"end":26},"obj":"Chemical"},{"id":"1507","span":{"begin":216,"end":219},"obj":"Chemical"},{"id":"1528","span":{"begin":30,"end":38},"obj":"Disease"},{"id":"1529","span":{"begin":306,"end":314},"obj":"Disease"}],"attributes":[{"id":"A1491","pred":"pubann:denotes","subj":"1491","obj":"Tax:9606"},{"id":"A1492","pred":"pubann:denotes","subj":"1492","obj":"Tax:9606"},{"id":"A1506","pred":"pubann:denotes","subj":"1506","obj":"MESH:D006886"},{"id":"A1507","pred":"pubann:denotes","subj":"1507","obj":"MESH:D006886"},{"id":"A1528","pred":"pubann:denotes","subj":"1528","obj":"MESH:C000657245"},{"id":"A1529","pred":"pubann:denotes","subj":"1529","obj":"MESH:C000657245"}],"text":"A prospective study of HCQ on COVID-19 patients (13 cases) admitted to the ICU in France showed that the first daily dose of 800 mg/1 time for 1 day, and 200 mg/2 times/day for 7 days was recommended to maintain the HCQ treatment level (1–2 mg/l) based on physiologically pharmacokinetic (PBPK) models for COVID-19 patients in ICU [67]."}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T163","span":{"begin":30,"end":38},"obj":"Disease"},{"id":"T164","span":{"begin":306,"end":314},"obj":"Disease"}],"attributes":[{"id":"A163","pred":"mondo_id","subj":"T163","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A164","pred":"mondo_id","subj":"T164","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"A prospective study of HCQ on COVID-19 patients (13 cases) admitted to the ICU in France showed that the first daily dose of 800 mg/1 time for 1 day, and 200 mg/2 times/day for 7 days was recommended to maintain the HCQ treatment level (1–2 mg/l) based on physiologically pharmacokinetic (PBPK) models for COVID-19 patients in ICU [67]."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1491","span":{"begin":39,"end":47},"obj":"Species"},{"id":"1492","span":{"begin":315,"end":323},"obj":"Species"},{"id":"1506","span":{"begin":23,"end":26},"obj":"Chemical"},{"id":"1507","span":{"begin":216,"end":219},"obj":"Chemical"},{"id":"1528","span":{"begin":30,"end":38},"obj":"Disease"},{"id":"1529","span":{"begin":306,"end":314},"obj":"Disease"}],"attributes":[{"id":"A1491","pred":"tao:has_database_id","subj":"1491","obj":"Tax:9606"},{"id":"A1492","pred":"tao:has_database_id","subj":"1492","obj":"Tax:9606"},{"id":"A1506","pred":"tao:has_database_id","subj":"1506","obj":"MESH:D006886"},{"id":"A1507","pred":"tao:has_database_id","subj":"1507","obj":"MESH:D006886"},{"id":"A1528","pred":"tao:has_database_id","subj":"1528","obj":"MESH:C000657245"},{"id":"A1529","pred":"tao:has_database_id","subj":"1529","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"A prospective study of HCQ on COVID-19 patients (13 cases) admitted to the ICU in France showed that the first daily dose of 800 mg/1 time for 1 day, and 200 mg/2 times/day for 7 days was recommended to maintain the HCQ treatment level (1–2 mg/l) based on physiologically pharmacokinetic (PBPK) models for COVID-19 patients in ICU [67]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T280","span":{"begin":0,"end":336},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"A prospective study of HCQ on COVID-19 patients (13 cases) admitted to the ICU in France showed that the first daily dose of 800 mg/1 time for 1 day, and 200 mg/2 times/day for 7 days was recommended to maintain the HCQ treatment level (1–2 mg/l) based on physiologically pharmacokinetic (PBPK) models for COVID-19 patients in ICU [67]."}